Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : U.S. Supreme Court rebuffs Merck appeal in hepatitis C patent fight with Gilead

01/19/2021 | 09:31am EST

Jan 19 (Reuters) - The U.S. Supreme Court on Tuesday rejected Merck & Co Inc's bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc for infringing a patent in a dispute over a blockbuster hepatitis C treatment.

The justices declined to take up Merck's appeal of a lower court's ruling that overturned the massive damages verdict after finding that Merck's patent was invalid. (Reporting by Andrew Chung in New York; Editing by Will Dunham)


© Reuters 2021
All news about GILEAD SCIENCES, INC.
02/25GILEAD SCIENCES  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
02/23GILEAD SCIENCES  : EU drugs regulator studying expanded use of COVID-19 drug rem..
RE
02/18GILEAD SCIENCES  : to Present at Upcoming Investor Conferences
BU
02/17Waiting for Big Pharma's Coronavirus Profits to Impress Wall Street -- Heard ..
DJ
02/16GILEAD SCIENCES  : and Wake Forest University School of Divinity Partner to Addr..
BU
02/16SUPREME COURT DECLINES TO HEAR IDENI : Dispute Surrounding The Enablement Standa..
AQ
02/11INSIDER TRENDS : Gilead Sciences Insider Sale Scales Back 90-Days of Buys
MT
02/11GILEAD SCIENCES  : SVB Leerink Adjusts Gilead Sciences' Price Target to $72 From..
MT
02/11GILEAD SCIENCES  : Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophyla..
AQ
02/10GILEAD SCIENCES  : Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophyla..
BU
More news
Financials (USD)
Sales 2021 24 857 M - -
Net income 2021 7 236 M - -
Net Debt 2021 17 538 M - -
P/E ratio 2021 11,5x
Yield 2021 4,52%
Capitalization 78 487 M 78 487 M -
EV / Sales 2021 3,86x
EV / Sales 2022 3,72x
Nbr of Employees 13 600
Free-Float 99,6%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 74,00 $
Last Close Price 62,46 $
Spread / Highest target 60,1%
Spread / Average Target 18,5%
Spread / Lowest Target -5,54%
EPS Revisions
Managers and Directors
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.5.39%78 487
VERTEX PHARMACEUTICALS-10.98%55 255
WUXI APPTEC CO., LTD.10.35%53 955
REGENERON PHARMACEUTICALS-6.74%46 924
BEIGENE, LTD.23.61%29 313
BIONTECH SE35.19%26 253